@misc{10818/62795,
year = {2024},
url = {http://hdl.handle.net/10818/62795},
abstract = {Objectives: Ototoxicity is a common disabling side effect of platinum-based chemotherapy. This study aimed to assess the evidence on the management of platinum-induced ototoxicity in adult cancer patients. Methods: Four databases were searched up to 1 November 2022. Original studies were included if they reported on a pharmacologic or non-pharmacologic intervention to prevent or treat platinum ototoxicity in adults. The articles' quality was assessed via two grading scales. Results: Nineteen randomised controlled trials and five quasi-experimental studies with 1673 patients were analysed. Eleven interventions were identified, nine pharmacological and two non-pharmacological. Six of the interventions (sodium thiosulphate, corticoids, sertraline, statins, multivitamins and D-methionine) showed mild benefits in preventing cisplatin-induced ototoxicity. Only one trial assessed corticoids as a potential treatment. Overall, only six trials were deemed with a low risk of bias. The majority of studies inadequately documented intervention-related adverse effects, thereby limiting safety conclusions. Conclusions: Current interventions have mild benefits in preventing cisplatin-induced ototoxicity in adult cancer patients. Sodium thiosulphate is the most promising intervention as a preventive strategy. Rigorous, high-quality research is warranted, encompassing an evaluation of all potential symptoms and innovative treatment modalities. © 2023 John Wiley & Sons Ltd.},
publisher = {Clinical Otolaryngology},
title = {Prevention and treatment of cisplatin-induced ototoxicity in adults: A systematic review},
doi = {10.1111/coa.14106},
author = {Correa-Morales J.E. and Giraldo-Moreno S. and Mantilla-Manosalva N. and Cuellar-Valencia L. and Borja-Montes O.F. and Bedoya-Muñoz L.J.},
}